Clincosm LogoSign in Get a demo

Mantle Cell Lymphoma

Showing 76 - 100 of 267
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Lymphoma Trial in Hangzhou (RD14-01 cell infusion)

Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • RD14-01 cell infusion
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Jul 6, 2022

Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (GEN3009, Epcoritamab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • +7 more
  • GEN3009
  • Epcoritamab
  • Tucson, Arizona
  • +31 more
Jul 1, 2022

Mantle Cell Lymphoma Trial in China (ICP-022)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Hefei, Anhui, China
  • +30 more
Jul 5, 2022

B-Cell Non-Hodgkin Lymphoma, DLBCL, Mantle Cell Lymphoma Trial in Duarte (Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous

Not yet recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-CD19-CAR CMV-specific T-lymphocytes
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Jun 28, 2022

Mantle Cell Lymphoma Trial in Baltimore (Venetoclax Oral Tablet [Venclexta])

Recruiting
  • Mantle Cell Lymphoma
  • Venetoclax Oral Tablet [Venclexta]
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jun 29, 2022

Mantle Cell Lymphoma Trial in Beijing

Recruiting
  • Mantle Cell Lymphoma
    • Beijing, Beijing, China
      Hongmei Third Jing
    Jun 20, 2022

    B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (Cirmtuzumab (2-16

    Recruiting
    • B-cell Chronic Lymphocytic Leukemia
    • +3 more
    • Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
    • +5 more
    • Duarte, California
    • +12 more
    Jun 16, 2022

    Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

    Active, not recruiting
    • Grade 1 Follicular Lymphoma
    • +6 more
    • Palo Alto, California
      Stanford University, School of Medicine
    Jun 13, 2022

    Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

    Suspended
    • Mantle Cell Lymphoma
    • Duarte, California
      City of Hope Medical Center
    Jun 7, 2022

    B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Taipei (RPM

    Terminated
    • B-cell Acute Lymphoblastic Leukemia
    • +7 more
    • RPM CD19-mbIL15-CAR-T cells
    • Taipei, Taiwan
      National Taiwan University Hospital
    May 11, 2022

    Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,

    Terminated
    • Non-Hodgkins Lymphoma
    • +6 more
    • Huntsville, Alabama
    • +1 more
    May 5, 2022

    CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma Trial in Cincinnati, Columbus, Salt Lake City (LP-168)

    Recruiting
    • CLL/SLL
    • +6 more
    • Cincinnati, Ohio
    • +2 more
    May 7, 2022

    B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

    Active, not recruiting
    • B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Anti-OX40 Antibody BMS 986178
    • +3 more
    • Palo Alto, California
      Stanford University, School of Medicine
    May 3, 2022

    Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma Trial in Guangzhou (Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib

    Recruiting
    • Mantle Cell Lymphoma
    • Newly-diagnosed Mantle Cell Lymphoma
    • Zanubrutinib and Rituximab
    • +2 more
    • Guangzhou, Guangdong, China
    • +2 more
    May 6, 2022

    Mantle Cell Lymphoma Trial in Hackensack (Lenalidomide, Ibrutinib, Rituximab)

    Active, not recruiting
    • Mantle Cell Lymphoma
    • Hackensack, New Jersey
      The Cancer Center at Hackensack University Medical Center
    May 3, 2022

    Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma Trial in San Francisco (Fludarabine, Cyclophosphamide,

    Recruiting
    • Refractory Non-Hodgkin Lymphoma
    • +8 more
    • San Francisco, California
      University of California, San Francisco
    May 2, 2022

    Mantle Cell Lymphoma Trial (parsaclisib, rituximab, bendamustine)

    Withdrawn
    • Mantle Cell Lymphoma
    • (no location specified)
    Apr 22, 2022

    Mantle Cell Lymphoma Trial in France, Germany (Abemaciclib)

    Active, not recruiting
    Has Results
    • Mantle Cell Lymphoma
    • Lille, France
    • +6 more
    Apr 6, 2022

    Mantle Cell Lymphoma Trial in Seoul (RB/RBAC alternating, RB)

    Not yet recruiting
    • Mantle Cell Lymphoma
    • RB/RBAC alternating
    • RB
    • Seoul, Gangnam-Gu, Korea, Republic of
      Samsung Medical Center
    Apr 18, 2022

    DLBCL, MCL, and FL Patients Undergoing CAR Therapy

    Not yet recruiting
    • Follicular Lymphoma
    • +2 more
    • ClonoSEQ
    • Palo Alto, California
      Stanford Cancer Center
    Apr 19, 2022

    Lymphoma, Lymphoma, B-Cell, Leukemia Trial in Houston (Digital Health Coaching)

    Recruiting
    • Lymphoma
    • +6 more
    • Digital Health Coaching
    • Houston, Texas
      The University of Texas MD Anderson Cancer Center
    Apr 12, 2022

    Mantle Cell Lymphoma Trial in Busan (Ixazomib)

    Recruiting
    • Mantle Cell Lymphoma
    • Busan, Western, Korea, Republic of
      Kosin University Gospel Hospital
    Mar 31, 2022

    Mantle Cell Lymphoma Trial in United States (lenalidomide, rituximab)

    Active, not recruiting
    Has Results
    • Mantle Cell Lymphoma
    • Tampa, Florida
    • +3 more
    Mar 26, 2022

    Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia Trial in Australia,

    Recruiting
    • Follicular Lymphoma
    • +7 more
    • Louisville, Kentucky
    • +4 more
    Mar 11, 2022

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in Worldwide (Ibrutinib)

    Enrolling by invitation
    • Chronic Lymphocytic Leukemia
    • +6 more
    • Duarte, California
    • +165 more
    Mar 24, 2022